Novo Nordisk A/S
NOVO-B
Pozycja w akcjach
#109
Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the... Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Cena akcji
$39.24
Kapitalizacja rynkowa
$173.16B
Zmiana (1 dzień)
-5.26%
Zmiana (1 rok)
-28.83%
Kraj
DK
Handel Novo Nordisk A/S (NOVO-B)
Kategoria
Healthcare
Historia stopy dywidendy dla Novo Nordisk A/S (NOVO-B)
Stopa dywidendy (TTM) dla Novo Nordisk A/S (symbol akcji: NOVO-B) na dzień 2026 wynosi: 0
Średnia stopa dywidendy z ostatnich 5 lat: 0.00%
Średnia stopa dywidendy z ostatnich 5 lat: 0.00%
Historia stopy dywidendy dla Novo Nordisk A/S (NOVO-B) od 2026 do 2026
Stopa dywidendy na koniec każdego roku (TTM)
| Rok | Stopa dywidendy | Zmień |
|---|---|---|
| Za mało danych dla podanych dat. | ||
Stopy dywidendy (TTM) dla podobnych firm lub konkurencji
| Firma | Stopa dywidendy | Kraj |
|---|---|---|
| 0.55% |
US
|
|
| 2.08% |
US
|
|
| 2.44% |
US
|
|
| 2.31% |
US
|
|
| 2.69% |
CH
|
